Cargando…

Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy

BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Renato D, Lokhnygina, Yuliya, Hasselblad, Victor, Newby, Kristin L, Yow, Eric, Granger, Christopher B, Armstrong, Paul W, Hochman, Judith S, Mills, James S, Ruzyllo, Witold, Mahaffey, Kenneth W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662641/
https://www.ncbi.nlm.nih.gov/pubmed/23782531
http://dx.doi.org/10.1186/1745-6215-14-123
_version_ 1782270857593225216
author Lopes, Renato D
Lokhnygina, Yuliya
Hasselblad, Victor
Newby, Kristin L
Yow, Eric
Granger, Christopher B
Armstrong, Paul W
Hochman, Judith S
Mills, James S
Ruzyllo, Witold
Mahaffey, Kenneth W
author_facet Lopes, Renato D
Lokhnygina, Yuliya
Hasselblad, Victor
Newby, Kristin L
Yow, Eric
Granger, Christopher B
Armstrong, Paul W
Hochman, Judith S
Mills, James S
Ruzyllo, Witold
Mahaffey, Kenneth W
author_sort Lopes, Renato D
collection PubMed
description BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct size include the observed CK-MB peak and calculated CK-MB area under the curve (AUC). We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes. METHODS: Of 1,850 STEMI patients treated with reperfusion therapy in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) (percutaneous coronary intervention (PCI)-treated) and the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) (fibrinolytic-treated) trials, 1,718 (92.9%) (COMMA, n = 868; COMPLY, n = 850) had at least five of nine protocol-required CK-MB measures. In addition to traditional methods, curve-fitting techniques were used to determine CK-MB AUC and estimated peak CK-MB. Cox proportional hazards modeling assessed the univariable associations between infarct size and mortality, and the composite of death, heart failure, shock and stroke at 90 days. RESULTS: In COMPLY, CK-MB measures by all methods were significantly associated with higher mortality (hazard ratio range per 1,000 units increase: 1.09 to 1.13; hazard ratio range per 1 standard deviation increase: 1.41 to 1.62; P <0.01 for all analyses). In COMMA, the associations were similar but did not reach statistical significance. For the composite outcome of 90-day death, heart failure, shock and stroke, the associations with all CK-MB measures were statistically significant in both the COMMA and COMPLY trials. CONCLUSIONS: Sophisticated curve modeling is an alternative to infarct-size quantification in STEMI patients, but it provides information similar to that of more traditional methods. Future studies will determine whether the same conclusion applies in circumstances other than STEMI, or to studies with different frequencies and patterns of CK-MB data collection.
format Online
Article
Text
id pubmed-3662641
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36626412013-06-05 Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy Lopes, Renato D Lokhnygina, Yuliya Hasselblad, Victor Newby, Kristin L Yow, Eric Granger, Christopher B Armstrong, Paul W Hochman, Judith S Mills, James S Ruzyllo, Witold Mahaffey, Kenneth W Trials Research BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct size include the observed CK-MB peak and calculated CK-MB area under the curve (AUC). We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes. METHODS: Of 1,850 STEMI patients treated with reperfusion therapy in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) (percutaneous coronary intervention (PCI)-treated) and the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) (fibrinolytic-treated) trials, 1,718 (92.9%) (COMMA, n = 868; COMPLY, n = 850) had at least five of nine protocol-required CK-MB measures. In addition to traditional methods, curve-fitting techniques were used to determine CK-MB AUC and estimated peak CK-MB. Cox proportional hazards modeling assessed the univariable associations between infarct size and mortality, and the composite of death, heart failure, shock and stroke at 90 days. RESULTS: In COMPLY, CK-MB measures by all methods were significantly associated with higher mortality (hazard ratio range per 1,000 units increase: 1.09 to 1.13; hazard ratio range per 1 standard deviation increase: 1.41 to 1.62; P <0.01 for all analyses). In COMMA, the associations were similar but did not reach statistical significance. For the composite outcome of 90-day death, heart failure, shock and stroke, the associations with all CK-MB measures were statistically significant in both the COMMA and COMPLY trials. CONCLUSIONS: Sophisticated curve modeling is an alternative to infarct-size quantification in STEMI patients, but it provides information similar to that of more traditional methods. Future studies will determine whether the same conclusion applies in circumstances other than STEMI, or to studies with different frequencies and patterns of CK-MB data collection. BioMed Central 2013-05-02 /pmc/articles/PMC3662641/ /pubmed/23782531 http://dx.doi.org/10.1186/1745-6215-14-123 Text en Copyright © 2013 Lopes et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Lopes, Renato D
Lokhnygina, Yuliya
Hasselblad, Victor
Newby, Kristin L
Yow, Eric
Granger, Christopher B
Armstrong, Paul W
Hochman, Judith S
Mills, James S
Ruzyllo, Witold
Mahaffey, Kenneth W
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
title Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
title_full Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
title_fullStr Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
title_full_unstemmed Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
title_short Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
title_sort methods of creatine kinase-mb analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662641/
https://www.ncbi.nlm.nih.gov/pubmed/23782531
http://dx.doi.org/10.1186/1745-6215-14-123
work_keys_str_mv AT lopesrenatod methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT lokhnyginayuliya methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT hasselbladvictor methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT newbykristinl methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT yoweric methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT grangerchristopherb methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT armstrongpaulw methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT hochmanjudiths methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT millsjamess methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT ruzyllowitold methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy
AT mahaffeykennethw methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy